Ophthalmic Innovation
Advancing the industry’s most comprehensive ophthalmic surgical and pharmaceutical pipeline
At Glaukos, we are dedicated to addressing the greatest unmet needs of the global ophthalmic market, for physicians and for patients. That’s why we’ve spent more than a decade re-investing in R&D and clinical trial programs to develop and advance a deep pipeline of novel therapies currently being evaluated in FDA clinical trials, while leading the industry in clinical support and patient education resources. And it’s why we’re seeking to leverage our platform technologies to build an unrivaled portfolio of next-generation surgical and pharmaceutical therapies in glaucoma, corneal health, and retinal disease.
We’ve achieved many firsts in clinical studies and over the past several years, Glaukos has reinvested approximately 30% of all sales back into research and development activities – all to relentlessly advance our goal of creating and delivering transformative therapies for patients struggling with eye diseases and the skilled surgeons dedicated to their healing.
Our Strategy for Long-Term Growth
Pipeline Currently Includes 14 Candidates, Plus Additional Undisclosed Programs
| Product/Candidate | Indication | U.S. Status | ||||||
|---|---|---|---|---|---|---|---|---|
| Product/CandidateiStent / iStent inject / iStent inject W | IndicationMild-to-moderate primary open-angle glaucoma in combination with cataract surgery | U.S. StatusApproved | ||||||
| Product/CandidateiPrime | IndicationDelivery of viscoelastic during ophthalmic surgery | U.S. StatusApproved | ||||||
| Product/CandidateiAccess | IndicationManual cutting of TM during ophthalmic surgery | U.S. StatusApproved | ||||||
| Product/CandidateiStent infinite | IndicationGlaucoma (failed on prior medical and surgical therapy) Standalone | U.S. StatusApproved | ||||||
| Product/CandidateiStent infinite | IndicationEarlier Intervention Glaucoma Standalone | U.S. StatusPre-clinical | ||||||
| Product/CandidatePRESERFLO MicroShunt | IndicationGlaucoma Standalone | U.S. StatusPMA non-approvable; review ongoing | ||||||
| Pre-Clinical | Phase 1 | Phase 2 | Phase 3 | FDA Submission | Approved1 | |||
| Product/Candidate | Indication | U.S. Status | ||||||
|---|---|---|---|---|---|---|---|---|
| Product/CandidateiDose TR | IndicationOcular Hypertension - Refractory Glaucoma | U.S. StatusFDA Submission | ||||||
| Product/CandidateiDose TREX | IndicationOcular Hypertension - Refractory Glaucoma | U.S. StatusPre-clinical | ||||||
| Product/CandidateiDose ROCK | IndicationOcular Hypertension - Refractory Glaucoma | U.S. StatusPre-clinical | ||||||
| Pre-Clinical | Phase 1 | Phase 2 | Phase 3 | FDA Submission | Approved1 | |||
| Product/Candidate | Indication | U.S. Status | ||||||
|---|---|---|---|---|---|---|---|---|
| Product/CandidateGLK-301 | IndicationDry Eye Disease | U.S. StatusPhase 2 | ||||||
| Product/CandidateGLK-302 | IndicationPresbyopia | U.S. StatusPhase 2 | ||||||
| Product/CandidateGLK-311 | IndicationGlaucoma | U.S. StatusPre-clinical | ||||||
| Product/CandidateGLK-311 | IndicationBlepharitis | U.S. StatusPre-clinical | ||||||
| Pre-Clinical | Phase 1 | Phase 2 | Phase 3 | FDA Submission | Approved1 | |||
| Product/Candidate | Indication | U.S. Status | ||||||
|---|---|---|---|---|---|---|---|---|
| Product/CandidatePhotrexa (Epi-off) | IndicationKeratoconus | U.S. StatusApproved | ||||||
| Product/CandidateEpioxa (Epi-on) | IndicationKeratoconus | U.S. StatusPhase 3 | ||||||
| Product/CandidateThird-Generation | IndicationKeratoconus | U.S. StatusPhase 2 | ||||||
| Pre-Clinical | Phase 1 | Phase 2 | Phase 3 | FDA Submission | Approved1 | |||
| Product/Candidate | Indication | U.S. Status | ||||||
|---|---|---|---|---|---|---|---|---|
| Product/CandidateGLK-401 (IVT Multi-Kinase Inhibitor) | IndicationAge-Related Macular Degeneration (AMD) Diabetic Macular Edema (DME) | U.S. StatusPre-clinical | ||||||
| Product/CandidateGLK-411 (IVT Triamcinolone) | IndicationDME | U.S. StatusPre-clinical | ||||||
| Pre-Clinical | Phase 1 | Phase 2 | Phase 3 | FDA Submission | Approved1 | |||
*2019 Glaukos fiscal year
1 In US